Browsing by Author "Alan, Ozkan"
Now showing items 1-4 of 4
-
Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye
Unal, Caglar; Selcuk, Nalan Alan; Biricik, Fatih Selcuk; Alan, Ozkan; Ordu, Cetin; Selvi, Oguzhan; Sakin, Abdullah (Kare Publ, 2023)Objectives: This study aimed to evaluate the clinical outcomes, including progression-free survival (PFS), overall sur-vival (OS), Objective Response Rate (ORR), and Disease Control Rate (DCR), in patients received ... -
Clinical and inflammation marker features of cancer patients with COVID-19: data of Istanbul, Turkey multicenter cancer patients (2020-2022)
Unal, Caglar; Tuncer, Gulsah; Copur, Betul; Pilanci, Kezban Nur; Okutur, Kerem Sadi; Yararbas, Kanay; Alan, Ozkan (Taylor & Francis Ltd, 2023)ObjectiveWe aimed to identify a rapid, accurate, and accessible biomarker in the early stages of COVID-19 that can determine the prognosis of the disease in cancer patients.MethodsA total number of 241 patients with solid ... -
Prognostic Role of Inflammatory and Nutritional Indices in NSCLC Patients Treated with Immune Checkpoint Inhibitors: Retrospective, Multicenter, Turkish Oncology Group Study of Overall and Elderly Populations
Alan, Ozkan; Telli, Tugba Akin; Akbas, Sinem; Isik, Selver; Cavdar, Eyyub; Karaboyun, Kubilay; Cetinkaya, Aysegul Merc (Mdpi, 2025)Background and Objectives: Despite advances in immunotherapy, predicting survival outcomes in patients with non-small-cell lung cancer (NSCLC) remains challenging. Inflammatory and nutritional indices such as the Prognostic ... -
Real-World Outcomes in BRAF-Mutant Non-small Cell Lung Cancer: A Multicenter Analysis From the Turkish Oncology Group
Akın Telli, Tuğba; Tatli, Ali Murat; Alan, Ozkan; Keskin, Gul Sema Yildiran; Karadurmuş, Nuri; Karakaya, Serdar; Kaplan, Muhammet Ali (Elsevier Inc., 2025)Background: Real-world data on BRAF-mutant non-small cell lung cancer (NSCLC) remain limited, particularly regarding outcomes with dabrafenib plus trametinib (D + T). Methods: This multicenter retrospective study included ...
